SCHEMBL30765849

SCHEMBL30765849

COc1ccc(CNc2cnc(-c3ccccc3)n(CC(=O)NCc3cc4cnccc4[nH]3)c2=O)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.46
F3 P13726 1/20 0.41
CYP1A2 P05177 5/20 0.41
CYP3A4 P08684 5/20 0.41
CYP2D6 P10635 5/20 0.41
CLK4 Q9HAZ1 5/20 0.41
CYP2C19 P33261 4/20 0.41
LMNA P02545 4/20 0.41
USP2 O75604 3/20 0.41
HSD17B10 Q99714 3/20 0.41
CYP2C9 P11712 2/20 0.41
TSHR P16473 2/20 0.41
ALOX15 P16050 1/20 0.41
MAPT P10636 6/20 0.40
TAS1R3 Q7RTX0 2/20 0.40
TAS1R1 Q7RTX1 2/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765437 0.87 HDAC6 (0.41) F3ALOX15KDM4EALDH1A1TDP1
SCHEMBL31558592 0.83 KDM4C (0.45) KDM4CF3CYP1A2CYP3A4CYP2D6
SCHEMBL30765634 0.83 CASP1 (0.42) NTRK1CMA1CTRC
SCHEMBL30766049 0.82 NTRK1 (0.43) F3NTRK1CMA1CTRC
SCHEMBL30765582 0.82 KDM4C (0.42) KDM4CCYP1A2CYP3A4CYP2D6CLK4
SCHEMBL30765482 0.81 KDM4C (0.50) KDM4CCYP1A2CYP3A4CYP2D6CLK4
Hydrochloric Acid SCHEMBL30765434 0.81 NTRK1 (0.43) F3NTRK1CMA1CTRC
SCHEMBL30765489 0.81 F2 (0.39) KDM4CF3NTRK1CMA1CTRC
SCHEMBL30765961 0.81 NTRK1 (0.43) F3NTRK1CMA1CTRC
SCHEMBL30765886 0.80 CASP1 (0.40) CYP3A4LMNANTRK1MAPK1CMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed